Semnur Pharmaceuticals, Inc. (SMNR)

Market Cap	2.63B
Revenue (ttm)	n/a
Net Income (ttm)	-3.74M
Shares Out	292.48M
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	159
Average Volume	651
Open	9.00
Previous Close	19.00
Day's Range	9.00 - 9.00
52-Week Range	9.00 - 20.00
Beta	0.34
RSI	40.40
Earnings Date	Dec 26, 2025

About Semnur Pharmaceuticals

Semnur Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its lead product candidate is SP-102, an opioid novel injectable corticosteroid gel formulation for patients with moderate to severe LRP. The company was founded in 2013 and is headquartered in Palo Alto, California. Semnur Pharmaceuticals, Inc. operates as a subsidiary of Scilex Holding Company.

• Industry: Pharmaceutical Preparations
• Founded: 2013
• Employees: 1
• Stock Exchange: OTCMKTS
• Ticker Symbol: SMNR